Chemotherapy for brain tumors with polymer drug delivery

Attenello, Frank J.; Raza, Shaan M.; DiMeco, Francesco; Olivi, Alessandro

doi:10.1016/b978-0-444-52138-5.00022-0

Cited by 13 publications

(5 citation statements)

References 116 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7C). Similar to the findings with TMZ, although X10 and X16 GICs were resistant to carmustine (another DNA alkylating agent used to treat GBM patients [57]), a combination treatment of carmustine and PFI-3 rendered the X10 and X16 GICs sensitive to the drugs (Fig. 7D).…”

Section: Pharmacologic Inhibition Of Brg1 Sensitizes X16 Gics To Tmzsupporting

confidence: 72%

Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells

et al. 2018

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a highly aggressive and malignant brain tumor that is refractory to existing therapeutic regimens, which reflects the presence of stem-like cells, termed Glioma-Initiating Cells (GICs). The complex interactions between different signaling pathways and epigenetic regulation of key genes may be critical in the maintaining GICs in their stem-like state. Although several signaling pathways have been identified as being dysregulated in GBM, the prognosis of GBM patients remains miserable despite improvements in targeted therapies. In this report, we identified that BRG1, the catalytic subunit of the SWI/SNF chromatin remodeling complex, plays a fundamental role in maintaining GICs in their stem-like state. In addition, we identified a novel mechanism by which BRG1 regulates glycolysis genes critical for GICs. BRG1 downregulates the expression of TXNIP, a negative regulator of glycolysis. BRG1 knockdown also triggered the STAT3 pathway, which led to TXNIP activation. We further identified that TXNIP is an STAT3-regulated gene. Moreover, BRG1 suppressed the expression of interferon-stimulated genes, which are negatively regulated by STAT3 and regulate tumorigenesis. We further demonstrate that BRG1 plays a critical role in the drug resistance of GICs and in GIC-induced tumorigenesis. By genetic and pharmacological means, we found that inhibiting BRG1 can sensitize GICs to chemotherapeutic drugs, temozolomide and carmustine. Our studies suggest that BRG1 may be a novel therapeutic target in GBM. The identification of the critical role that BRG1 plays in GIC stemness and chemosensitivity will inform the development of better targeted therapies in GBM and possibly other cancers. Stem Cells 2018.

show abstract

Section: Pharmacologic Inhibition Of Brg1 Sensitizes X16 Gics To Tmzsupporting

confidence: 72%

Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Therefore, the search for alternative compounds with biological activity capable of mitigating the harmful effects of external DNA-damaging agents on our health, such as camptothecin and BPA, should be considered. The adverse effect caused by camptothecin affects topoisomerase I, allowing the cleavage of DNA but inhibiting the subsequent ligation resulting in DNA double-strand breaks (Attenello et al 2012 ). This agent is a plant alkaloid, widely used as an anti-tumor drug in chemotherapy (Pund and Joshi 2017 ).…”

Section: Resultsmentioning

confidence: 99%

Evaluation of biotechnological processing through solid-state fermentation of oilseed cakes on extracts bioactive potential

et al. 2023

View full text Add to dashboard Cite

Oilseed cakes (OC) are natural sources of lignocellulosic biomass, produced every year in large amounts. In addition to their main applications as animal feed, plant or soil fertilizer, and compost, they present enormous potential for being used in biotechnological processes for the obtainment and extraction of valuable bioactive compounds. This work evaluated the effect of solid-state fermentation on the bioactive properties of extracts obtained from the bioprocessing of OC and evaluated the effect of solvents on the recovery of compounds with higher bioactive potential. A general decrease of EC50 values was observed for fermented extracts obtained using a mixture of water/methanol (1:1) as extraction solvent. A decrease in the minimum inhibitory concentration was observed for fermented water extracts compared to non-fermented. Additionally, growth inhibition of Listeria monocytogenes was observed when using aqueous methanolic fermented extracts. These extracts also exhibited a higher percentage of growth reduction against phytopathogenic fungi, and some extracts exhibited increased protection against genotoxic agents such as camptothecin and bisphenol A. It was demonstrated that bioprocessing of OC through SSF is an effective approach to obtaining valuable compounds with bioactive properties for use in the food, pharmaceutical or cosmetic industries.

show abstract

“…Given the localized placement of the wafer to residual tumor cells, this approach conferred advantages over systemic administration of BCNU. When delivered systemically, BCNU is rapidly metabolized with a relatively short half-life and studies have shown limited clinical efficacy and severe hematological side effects following therapy [ 31 , 32 , 42 , 43 ]. The intermittent exposure of BCNU to tumor cells following intravenous administration is a shortcoming of systemic chemotherapy treatment which ultimately impacts survival rates.…”

Section: Clinical Need For Drug Delivery Systemsmentioning

confidence: 99%

Glioblastoma Multiforme—A Look at the Past and a Glance at the Future

King

Benhabbour

2021

Pharmaceutics

View full text Add to dashboard Cite

Gliomas are the most common type of brain tumor that occur in adults and children. Glioblastoma multiforme (GBM) is the most common, aggressive form of brain cancer in adults and is universally fatal. The current standard-of-care options for GBM include surgical resection, radiotherapy, and concomitant and/or adjuvant chemotherapy. One of the major challenges that impedes success of chemotherapy is the presence of the blood–brain barrier (BBB). Because of the tightly regulated BBB, immune surveillance in the central nervous system (CNS) is poor, contributing to unregulated glioma cell growth. This review gives a comprehensive overview of the latest advances in treatment of GBM with emphasis on the significant advances in immunotherapy and novel therapeutic delivery strategies to enhance treatment for GBM.

show abstract

Chemotherapy for brain tumors with polymer drug delivery

Cited by 13 publications

References 116 publications

Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells

Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells

Evaluation of biotechnological processing through solid-state fermentation of oilseed cakes on extracts bioactive potential

Glioblastoma Multiforme—A Look at the Past and a Glance at the Future

Contact Info

Product

Resources

About